8NE.F LISATA THERAP.INC.DL-001

Healthcare Biotechnology Frankfurt Exchange
0.9500 EUR
Close of Nov 11, 2026
0.7350 4.34
Market cap
EUR 10.3M
P/E
-
P/B
1.21x
ROE
-180.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8NE.F undervalued?

Graham number

The Graham number of LISATA THERAP.INC.DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LISATA THERAP.INC.DL-001 fundamental analysis

No fundamental analysis for LISATA THERAP.INC.DL-001 yet.

LISATA THERAP.INC.DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LISATA THERAP.INC.DL-001

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of …

Full company profile